α-Methylacyl-CoA racemase (AMACR) serves as a prognostic biomarker for the early recurrence/metastasis of HCC

Xu, Beibei; Cai, Zhixiong; Zeng, Yongyi; Du, Xiaohong; Huang, Aimin; Liu, Xiaolong; Liu, Jingfeng

doi:10.1136/jclinpath-2014-202378

Cited by 17 publications

(8 citation statements)

References 27 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AMACR expression was commonly found in prostate cancer tissue and was a key diagnostic marker 4 . Mounting evidences have suggested that high expression of AMACR represents as an adverse prognostic factor in a wide variety of cancers, such as gastric adenocarcinoma, hepatocellular carcinoma, gallbladder carcinoma, nasopharyngeal carcinoma, gastrointestinal stromal tumor and myxofibrosarcoma 8 - 11 , 13 , 14 . Similar finding was also found in our study that there was a link between AMACR overexpression and poor patients' outcomes in oral SCC.…”

Section: Discussionmentioning

confidence: 99%

AMACR overexpression acts as a negative prognostic factor in oral squamous cell carcinoma

Lee

Chang

et al. 2018

Int. J. Med. Sci.

View full text Add to dashboard Cite

Background: Alpha-methylacyl-CoA racemase (AMACR) is a key enzyme responsible for the metabolism of branched-chain fatty acids. It has been found to be an important prognostic factor in numerous types of cancers. This study was aimed to investigate the expression of AMACR and its prognostic significance in patients with oral squamous cell carcinoma (SCC).Methods: Analysis of publicly available microarray data of oral SCC revealed that AMACR was significantly upregulated in tumor tissue compared with normal mucosa. We further assessed the protein expression of AMACR in 164 patients with oral SCC by immunohistochemistry. The prognostic impact of AMACR expression and its association with various clinicopathological parameters were statistically analyzed.Results: AMACR overexpression was significantly associated with advanced tumor status (P=0.001), advanced nodal status (P=0.036), increased vascular invasion (P=0.026) and increased perineural invasion (P=0.004). Patients with high expression level of AMACR had significantly worse disease-specific survival (DSS), distant metastasis-free survival (DMFS) and local recurrence-free survival (LRFS) (all P<0.0001). In multivariate analysis, AMACR overexpression was also an independent negative prognostic factor for DSS (hazard ratio [HR]: 4.410, 95% confidence interval [CI]: 2.285-8.511, P<0.001), DMFS (HR: 5.157, 95% CI: 2.756-9.651, P<0.001) and LRFS (HR: 4.462, 95% CI: 2.429-8.198, P<0.001).Conclusions: High expression of AMACR was not only a key adverse prognostic factor but also a potential therapeutic target in oral SCC.

show abstract

Section: Discussionmentioning

confidence: 99%

AMACR overexpression acts as a negative prognostic factor in oral squamous cell carcinoma

Lee

Chang

et al. 2018

Int. J. Med. Sci.

View full text Add to dashboard Cite

show abstract

“…Paraffin blocks from HCC and normal tissues were constructed into tissue microarray (TMA) and reported previously. 12 TMA blocks were cut into 4.5 μM sections. TMA sections were stained for ADAMTS5 expression using a rabbit polyclonal antibody against ADAMTS5 at a dilution of 1:100 (#ab41037; Abcam, Cambridge, UK), for VEGF using a mouse monoclonal antibody against VEGF (MAIXIN-BIO, Fuzhou, People’s Republic of China), and for microvessels using a rabbit monoclonal antibody against CD34 at a dilution of 1:400 (#ab81289; Abcam) according to a previous study.…”

Section: Methodsmentioning

confidence: 99%

Lost expression of ADAMTS5 protein associates with progression and poor prognosis of hepatocellular carcinoma

Li¹,

Xiong²,

Yang³

et al. 2015

DDDT

View full text Add to dashboard Cite

Altered expression of ADAMTS5 is associated with human carcinogenesis and tumor progression. However, the role of ADAMTS5 in hepatocellular carcinoma (HCC) is unclear. This study analyzed ADAMTS5 expression in HCC tissues and tested for association with clinicopathological and survival data from HCC patients and then explored the role of ADAMTS5 in HCC cells in vitro. Paraffin blocks from 48 HCC patients were used to detect ADAMTS5 and vascular endothelial growth factor (VEGF) expression and microvessel density (MVD). A normal liver cell line and HCC cell lines were used to detect ADAMTS5 expression and for ADAMTS5 manipulation. ADAMTS5 cDNA was stably transfected into HCC cells and ADAMTS5 expression assessed by Western blot analysis. Tumor cell-conditioned growth medium was used to assess human umbilical vein endothelial cell migration and Matrigel tube formation. Xenograft assay was performed to determine the role of ADAMTS5 in vivo. The data showed that the expression of ADAMTS5 was reduced in HCC, which was inversely associated with VEGF expression, MVD, and tumor size and associated with poor overall survival of HCC patients. Lentivirus-mediated ADAMTS5 expression significantly inhibited tumor angiogenesis by downregulating in vitro expression of VEGF and inhibiting migration and tube formations, and also inhibited tumor growth and VEGF expression and reduced MVD in vivo in a mouse xenograft model. Taken together, these results suggest that ADAMTS5 plays a role in suppression of HCC progression, which could be further studied as a promising novel therapeutic target and a potential prognostic marker in HCC.

show abstract

“…This enzyme had been previously described as an immunohistological marker for PCa diagnosis [86,87], associated with poor prognosis in patients with localized PCa [88] and found to be overexpressed in PCa tissues [89]. Interestingly, AMACR has also been identified as a promising prognostic indicator in other cancer types, including gastric cancer [90] and hepatocellular [91] and nasopharyngeal [92] carcinomas.…”

Section: Pca Metabolic Biomarkers In Biofluidsmentioning

confidence: 99%

Metabolomics Contributions to the Discovery of Prostate Cancer Biomarkers

et al. 2019

View full text Add to dashboard Cite

Prostate cancer (PCa) is one of the most frequently diagnosed cancers and a leading cause of death among men worldwide. Despite extensive efforts in biomarker discovery during the last years, currently used clinical biomarkers are still lacking enough specificity and sensitivity for PCa early detection, patient prognosis, and monitoring. Therefore, more precise biomarkers are required to improve the clinical management of PCa patients. In this context, metabolomics has shown to be a promising and powerful tool to identify novel PCa biomarkers in biofluids. Thus, changes in polyamines, tricarboxylic acid (TCA) cycle, amino acids, and fatty acids metabolism have been reported in different studies analyzing PCa patients’ biofluids. The review provides an up-to-date summary of the main metabolic alterations that have been described in biofluid-based studies of PCa patients, as well as a discussion regarding their potential to improve clinical PCa diagnosis and prognosis. Furthermore, a summary of the most significant findings reported in these studies and the connections and interactions between the different metabolic changes described has also been included, aiming to better describe the specific metabolic signature associated to PCa.

show abstract

α-Methylacyl-CoA racemase (AMACR) serves as a prognostic biomarker for the early recurrence/metastasis of HCC

Cited by 17 publications

References 27 publications

AMACR overexpression acts as a negative prognostic factor in oral squamous cell carcinoma

AMACR overexpression acts as a negative prognostic factor in oral squamous cell carcinoma

Lost expression of ADAMTS5 protein associates with progression and poor prognosis of hepatocellular carcinoma

Metabolomics Contributions to the Discovery of Prostate Cancer Biomarkers

Contact Info

Product

Resources

About